Skip to content
Search

Latest Stories

Made in India Covid-19 vaccine likely by February, says Indian scientist

A senior Indian scientist on Thursday(5) said that an Indian government-backed Covid-19 vaccine likely to be launched by February 2021, earlier than expected.

Senior Indian Council of Medical Research (ICMR) scientist Rajni Kant told Reuters that last-stage trials begin this month and studies have so far showed it is safe and effective.


Bharat Biotech, a private company that is developing COVAXIN with the government-run ICMR, had earlier hoped to launch the vaccine only in the second quarter of next year.

"The vaccine has shown good efficacy," Rajni Kant, who is also a member of its Covid-19 task-force, said at the research body's New Delhi headquarters on Thursday.

"It is expected that by the beginning of next year, February or March, something would be available."

Bharat Biotech could not immediately be contacted.

A launch in February would make COVAXIN the first India-made vaccine to be rolled out.

India's cases of coronavirus infections rose by 50,201 cases on Thursday to 8.36 million, second only to the US. Deaths rose by 704, with the total now at 124,315. The daily rise in infections and deaths has slowed since a peak in mid-September.

Kant, who is the head of ICMR's research management, policy, planning and coordination cell, said it was up to the health ministry to decide if COVAXIN shots can be given to people even before the third-stage trials are over.

"It has shown safety and efficacy in the phase 1 and 2 trials and in the animal studies - so it is safe but you can't be 100 per cent sure unless the phase 3 trials are over," Kant said.

"There may be some risk, if you are ready to take the risk, you can take the vaccine. If necessary, the government can think of giving the vaccine in an emergency situation."

Health minister Harsh Vardhan said in September the government was considering granting an emergency authorisation for a Covid-19 vaccine, particularly for the elderly and people in high-risk workplaces.

Several leading vaccine candidates are already in final-stage testing. An experimental vaccine developed by Britain's AstraZeneca is among the most advanced ones, and Britain expects to roll it out in late December or early 2021.

AstraZeneca has signed several supply and manufacturing deals with companies and governments around the world, including with the Serum Institute of India.

Other late-stage vaccines are developed by Moderna Inc , Pfizer Inc with partner BioNTech SE, and Johnson & Johnson.

More For You

Prada 2026 sandals

Prada acknowledges Indian influence behind its Spring Summer 2026 men’s footwear

Instagram/prada/iStock

Prada finally acknowledges Kolhapuri chappals inspired 2026 sandals after Indian backlash over Milan show

Quick highlights:

• Prada confirms Indian roots behind 2026 ‘leather sandals’ after controversy
• Indian artisans and officials accused the brand of cultural appropriation
• The footwear resembles traditional Kolhapuri chappals with GI status
• Prada says designs are still in development and open to dialogue with India

Keep ReadingShow less
Anna Wintour

Wintour’s style of leadership earned her the nickname “Nuclear Wintour”

Getty Images

Anna Wintour steps down as editor of US Vogue after 37 years

Key points

  • Anna Wintour steps down as editor of US Vogue after 37 years
  • She will remain Vogue’s global editorial director and hold senior roles at Condé Nast
  • Wintour transformed US Vogue into a global fashion authority
  • The 75-year-old has received numerous honours, including the Presidential Medal of Freedom

End of an era at US Vogue

Anna Wintour has stepped down as the editor of US Vogue, bringing to a close a 37-year tenure that redefined the publication and saw her become one of the most influential figures in global fashion.

The announcement was made on Thursday (26 June) during a staff meeting in New York. Wintour, 75, will no longer oversee the day-to-day editorial operations of Vogue’s US edition. However, she will continue to serve as Vogue’s global editorial director and Condé Nast’s chief content officer, maintaining senior leadership roles across the company.

Keep ReadingShow less
Nadiya Hussain

She also reassured her followers that “exciting” new projects are on the way

Getty Images

“I won’t always be grateful” says Nadiya Hussain after BBC axes her cookery show

Key points

  • Nadiya Hussain confirms BBC will not renew her cookery series
  • Bake Off winner challenges expectations to remain “grateful”
  • She says hard work and talent, not luck, brought her success
  • Celebrities, including Annie Lennox and Fearne Cotton, show support

BBC ends decade-long collaboration with Bake Off star

Nadiya Hussain has spoken out after the BBC decided not to commission another cookery programme with her. The popular TV chef, who won The Great British Bake Off in 2015, shared her views on social media, stating that she “won’t always be grateful” and should not be expected to remain silent about career setbacks.

The decision ends a nearly 10-year working relationship between the broadcaster and Hussain, who has hosted several well-received cookery shows under the BBC banner. In her latest Instagram video, she addressed the public’s reaction and emphasised her right to expect more from her career.

Keep ReadingShow less
weight loss injections UK

The importance of vigilance as demand for these weight loss and diabetes drugs continues to grow

iStock

Hundreds report pancreas issues linked to weight loss injections as UK launches safety study

Key points

  • Almost 400 reports of acute pancreatitis linked to weight loss and diabetes jabs have been filed in the UK
  • Most cases involve popular GLP-1 drugs including Ozempic, Wegovy, and Mounjaro
  • Health officials are investigating possible genetic causes behind the side-effects
  • Patients hospitalised with pancreatitis encouraged to report symptoms via MHRA’s Yellow Card scheme
  • Adverse drug reactions cost the NHS an estimated £2.2bn annually

Health watchdog investigates spike in serious side-effects from GLP-1 drugs

UK health authorities have launched a study into the side effects of popular weight loss and diabetes drugs following a spike in reported cases of acute pancreatitis. Nearly 400 reports have been received via the Medicines and Healthcare products Regulatory Agency’s (MHRA) Yellow Card scheme, which monitors side effects and adverse reactions related to medicines and medical devices.

The medicines involved are GLP-1 receptor agonists – including semaglutide (marketed as Ozempic and Wegovy), liraglutide, and tirzepatide (branded as Mounjaro). The Yellow Card data shows that 181 of the cases involved tirzepatide alone.

Keep ReadingShow less
M&S launches strawberries

M&S’s latest offering taps into both tradition and innovation

The Wire

M&S launches strawberries and cream sandwich ahead of Wimbledon

Summary

  • M&S unveils limited edition strawberries and cream sandwich for £2.80
  • Inspired by Japanese 'sweet sandos', it features Red Diamond strawberries and whipped cream cheese
  • Available in stores now, found in the savoury sandwich aisle
  • Launch coincides with Wimbledon and British strawberry season
  • Wimbledon increases strawberries and cream price for first time in 15 years

New summer sandwich from M&S

Marks & Spencer has launched a limited edition M&S strawberry sandwich, combining classic British summer flavours with a Japanese twist. Priced at £2.80, the strawberries and cream sandwich is available in M&S stores now.

The dessert-style sandwich features M&S’s exclusive Red Diamond strawberries, whipped cream cheese, and sweetened bread. Despite its sweet contents, the product is found in the savoury sandwich section of M&S Food halls.

Keep ReadingShow less